Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 5 of 5 descriptions
| No. | 薬物名（臨床試験情報から抽出） | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ambrisentan plus Spironolactone | 2件: Ambrisentan Ambrisentan,Spironolactone (Mint-spironolactone) | 2件: Spironolactone
Spironolactone
(Spironolactone),Ambrisentan 💬 1. Ambrisentan plus Spironolactone
| 2件: EDNRA EDNRA,NR3C2 💬 | 8件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 8件: Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-recepto ... | 1件: 86 86 💬1. Ambrisentan plus Spironolactone
| |||||||||||||||||||||||||||||||||||
| 2 | Spironolactone | 1件: Spironolactone Spironolactone (Mint-spironolactone) | 1件: Spironolactone
Spironolactone
(Spironolactone) 💬2. Spironolactone
| 1件: NR3C2 NR3C2 💬2. Spironolactone
| 1件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption 💬 | 8件: 46 46, 58, 67, 86, 113, 210, 218, 225 💬2. Spironolactone
| |||||||||||||||||||||||||||||||||||
| 3 | Spironolactone (drug) | 1件: Spironolactone Spironolactone (Mint-spironolactone) | 1件: Spironolactone
Spironolactone
(Spironolactone) 💬3. Spironolactone (drug)
| 1件: NR3C2 NR3C2 💬3. Spironolactone (drug)
| 1件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption 💬 | 1件: 210 210 💬3. Spironolactone (drug)
| |||||||||||||||||||||||||||||||||||
| 4 | Spironolactone and conivaptan | 2件: Conivaptan Conivaptan,Spironolactone (Mint-spironolactone) | 2件: Spironolactone
Spironolactone
(Spironolactone),Conivaptan 💬 4. Spironolactone and conivaptan
| 3件: AVPR1A AVPR1A,AVPR2, NR3C2 💬 | 6件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬 6件: Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-recepto ... | 1件: 86 86 💬4. Spironolactone and conivaptan
| |||||||||||||||||||||||||||||||||||
| 5 | Spironolactone captopril carvedilol | 3件: Captopril Captopril,Carvedilol, Spironolactone (Mint-spironolactone) | 3件: Captopril
Captopril
,Carvedilol , Spironolactone (Spironolactone) 💬 5. Spironolactone captopril carvedilol
| 7件: ACE ACE,ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2, NR3C2 💬 | 19件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Chagas disease, Chemical carcinogenesis - receptor activation, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 19件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone-regulated sodium re ... | 1件: 86 86 💬5. Spironolactone captopril carvedilol
|